{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:04:37Z","timestamp":1789236277364,"version":"build-2803163510"},"reference-count":57,"publisher":"Impact Journals, LLC","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,2]]},"DOI":"10.18632\/oncotarget.10413","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T09:27:28Z","timestamp":1467797248000},"page":"50417-50427","source":"Crossref","is-referenced-by-count":112,"title":["HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review"],"prefix":"10.18632","volume":"7","author":[{"given":"Tengyun","family":"Wu","sequence":"first","affiliation":[{"name":"Air Force General Hospital of Chinese People's Liberation Army, Beijing 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geliang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Integrated Oncology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Li","sequence":"additional","affiliation":[{"name":"The Wright Center, Scranton, Pennsylvania 18510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Health Statistics, Faculty of Health Service, Second Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,6]]},"reference":[{"key":"1","unstructured":"All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012. World Health Organization. Website: http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx. Accessed September 27, 2015."},{"key":"2","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.18632\/oncotarget.3217","article-title":"CXCR4 over-expression and survival in cancer: a system review and meta-analysis","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"3","article-title":"Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies","author":"Curigliano","year":"2015","journal-title":"Pharmacology & therapeutics"},{"key":"4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1432-1033.1973.tb03188.x","article-title":"Isolation and characterisation of two calf-thymus chromatin non-histone proteins with high contents of acidic and basic amino acids","volume":"40","author":"Johns","year":"1973","journal-title":"European journal of biochemistry \/ FEBS"},{"key":"5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1126\/science.285.5425.248","article-title":"HMG-1 as a late mediator of endotoxin lethality in mice","volume":"285","author":"Molina","year":"1999","journal-title":"Science"},{"key":"6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2014.05.001","article-title":"HMGB1 in health and disease","volume":"40","author":"Zeh","year":"2014","journal-title":"Molecular aspects of medicine"},{"key":"7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0092-8674(92)90554-P","article-title":"The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene","volume":"71","author":"Maniatis","year":"1992","journal-title":"Cell"},{"key":"8","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1128\/MCB.23.7.2225-2238.2003","article-title":"Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma","volume":"23","author":"Fusco","year":"2003","journal-title":"Molecular and cellular biology"},{"key":"9","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1128\/MCB.12.2.894","article-title":"A poly(dA-dT) upstream activating sequence binds high-mobility group I protein and contributes to lymphotoxin (tumor necrosis factor-beta) gene regulation","volume":"12","author":"Ruddle","year":"1992","journal-title":"Molecular and cellular biology"},{"key":"10","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1158\/1078-0432.CCR-06-1953","article-title":"Masquerader: high mobility group box-1 and cancer","volume":"13","author":"Lotze","year":"2007","journal-title":"Clin Cancer Res"},{"key":"11","first-page":"1405","article-title":"Dealing with death: HMGB1 as a novel target for cancer therapy","volume":"4","author":"DeMarco","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbagrm.2009.11.014","article-title":"High-mobility group box 1 and cancer","volume":"1799","author":"Lotze","year":"2010","journal-title":"Biochimica et biophysica acta"},{"key":"13","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-13-0495","article-title":"HMGB1 in cancer: good, bad, or both?","volume":"19","author":"Tang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"14","first-page":"449","article-title":"Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer","volume":"27","author":"Fujii","year":"2007","journal-title":"Anticancer research"},{"key":"15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1477-7819-11-161","article-title":"Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients","volume":"11","author":"He","year":"2013","journal-title":"World journal of surgical oncology"},{"key":"16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/039463201402700410","article-title":"Clinical significance of hmgb1 expression in human gastric cancer","volume":"27","author":"Chen","year":"2014","journal-title":"International journal of immunopathology and pharmacology"},{"key":"17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00432-009-0706-1","article-title":"Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma","volume":"136","author":"Liu","year":"2010","journal-title":"Journal of cancer research and clinical oncology"},{"key":"18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/1471-2407-10-496","article-title":"Co-expression of nuclear and cytoplasmic HMGB1 is inversely associated with infiltration of CD45RO+ T cells and prognosis in patients with stage IIIB colon cancer","volume":"10","author":"Zhang","year":"2010","journal-title":"BMC cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1158\/1078-0432.CCR-10-2388","article-title":"Prognostic impact of DeltaTAp73 isoform levels and their target genes in colon cancer patients","volume":"17","author":"Dominguez","year":"2011","journal-title":"Clin Cancer Res"},{"key":"20","first-page":"5357","article-title":"Prognostic significance of high mobility group box 1 (HMGB1) expression in patients with colorectal cancer","volume":"34","author":"Mimori","year":"2014","journal-title":"Anticancer research"},{"key":"21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1479-5876-10-135","article-title":"High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy","volume":"10","author":"Chen","year":"2012","journal-title":"Journal of translational medicine"},{"key":"22","doi-asserted-by":"crossref","first-page":"e89097","DOI":"10.1371\/journal.pone.0089097","article-title":"The association of HMGB1 gene with the prognosis of HCC","volume":"9","author":"Chen","year":"2014","journal-title":"PloS one"},{"key":"23","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/j.1349-7006.2012.02358.x","article-title":"Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma","volume":"103","author":"Song","year":"2012","journal-title":"Cancer science"},{"key":"24","first-page":"2619","article-title":"Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy","volume":"133","author":"Holdenrieder","year":"2013","journal-title":"International journal of cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/path.2391","article-title":"Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma","volume":"216","author":"Liu","year":"2008","journal-title":"The Journal of pathology"},{"key":"26","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1016\/j.ejca.2010.07.016","article-title":"Elevated expression of HMGB1 in squamous-cell carcinoma of the head and neck and its clinical significance","volume":"46","author":"Qiu","year":"2010","journal-title":"Eur J Cancer"},{"key":"27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s12253-012-9539-3","article-title":"The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma","volume":"18","author":"Zhentao","year":"2012","journal-title":"Pathology oncology research: POR"},{"key":"28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","article-title":"Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma","volume":"13","author":"Nakano","year":"2013","journal-title":"BMC cancer"},{"key":"29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jso.23040","article-title":"Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer","volume":"106","author":"Huang","year":"2012","journal-title":"Journal of surgical oncology"},{"key":"30","doi-asserted-by":"crossref","first-page":"E1125","DOI":"10.1111\/j.1464-410X.2012.11277.x","article-title":"Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy","volume":"110","author":"Wu","year":"2012","journal-title":"BJU international"},{"key":"31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3325\/cmj.2009.50.455","article-title":"Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels","volume":"50","author":"Wang","year":"2009","journal-title":"Croatian medical journal"},{"key":"32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1196\/annals.1318.045","article-title":"Clinical proteomics and biomarker discovery","volume":"1022","author":"Liotta","year":"2004","journal-title":"Annals of the New York Academy of Sciences"},{"key":"33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbagrm.2009.11.008","article-title":"HMGB1: roles in base excision repair and related function","volume":"1799","author":"Wilson","year":"2010","journal-title":"Biochimica et biophysica acta"},{"key":"34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Weinberg","year":"2011","journal-title":"Cell"},{"key":"35","doi-asserted-by":"crossref","first-page":"e110626","DOI":"10.1371\/journal.pone.0110626","article-title":"The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review","volume":"9","author":"Yu","year":"2014","journal-title":"PloS one"},{"key":"36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1594","article-title":"High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal","volume":"5","author":"Tracey","year":"2005","journal-title":"Nature reviews Immunology"},{"key":"37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jpsychires.2015.02.016","article-title":"High-mobility group box-1 was released actively and involved in LPS induced depressive-like behavior","volume":"64","author":"Wang","year":"2015","journal-title":"Journal of psychiatric research"},{"key":"38","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2119\/2008-00034.Klune","article-title":"HMGB1: endogenous danger signaling","volume":"14","author":"Tsung","year":"2008","journal-title":"Mol Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0014-5793(96)01402-0","article-title":"Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation","volume":"400","author":"Pontremoli","year":"1997","journal-title":"FEBS letters"},{"key":"40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1189\/jlb.0506349","article-title":"HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay","volume":"81","author":"Harris","year":"2007","journal-title":"Journal of leukocyte biology"},{"key":"41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s10495-008-0303-9","article-title":"Immunogenic cell death modalities and their impact on cancer treatment","volume":"14","author":"Kroemer","year":"2009","journal-title":"Apoptosis"},{"key":"42","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/CJI.0b013e31804efc76","article-title":"High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy","volume":"30","author":"Zeh","year":"2007","journal-title":"J Immunother"},{"key":"43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1084\/jem.20111739","article-title":"HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4","volume":"209","author":"Uguccioni","year":"2012","journal-title":"The Journal of experimental medicine"},{"key":"44","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2006-02-004291","article-title":"Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature","volume":"108","author":"Griffioen","year":"2006","journal-title":"Blood"},{"key":"45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/35012626","article-title":"Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases","volume":"405","author":"Hori","year":"2000","journal-title":"Nature"},{"key":"46","first-page":"4805","article-title":"Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis","volume":"62","author":"Rauvala","year":"2002","journal-title":"Cancer research"},{"key":"47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/onc.2012.49","article-title":"Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1","volume":"32","author":"Griffioen","year":"2013","journal-title":"Oncogene"},{"key":"48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3892\/ol.2015.3907","article-title":"Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma","volume":"11","author":"Liu","year":"2016","journal-title":"Oncology letters"},{"key":"49","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00404-015-3864-1","article-title":"Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer","volume":"293","author":"Kim","year":"2016","journal-title":"Archives of gynecology and obstetrics"},{"key":"50","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1165\/rcmb.2009-0269OC","article-title":"High-mobility group box 1-mediated matrix metalloproteinase-9 expression in non-small cell lung cancer contributes to tumor cell invasiveness","volume":"43","author":"Chong","year":"2010","journal-title":"American journal of respiratory cell and molecular biology"},{"key":"51","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1002\/cncr.22731","article-title":"Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma","volume":"109","author":"Tsuchiya","year":"2007","journal-title":"Cancer"},{"key":"52","first-page":"164635","article-title":"Role of MALAT1 as a Prognostic Factor for Survival in Various Cancers: A Systematic Review of the Literature with Meta-Analysis","volume":"2015","author":"Niu","year":"2015","journal-title":"Disease markers"},{"key":"53","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1158\/0008-5472.CAN-11-3481","article-title":"Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma","volume":"72","author":"Yang","year":"2012","journal-title":"Cancer research"},{"key":"54","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000097","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS medicine"},{"key":"55","unstructured":"Phillips, Ball, Sackett. Oxford Centre for Evidence-based Medicine-levels of evidence [Updated 2009]. Centre for Evidence-Based Medicine. Website: http:\/\/www.cebm.net\/index.aspx?o=1025. Accessed September 27, 2015."},{"key":"56","unstructured":"Wells, Shea, O'Connell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta analyses. Ottawa Hospital Research Institute. Website: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed September 27, 2015."},{"key":"57","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Bombardier","year":"2006","journal-title":"Annals of internal medicine"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T06:21:24Z","timestamp":1589264484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,6]]},"references-count":57,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2016,8,2]]}},"alternative-id":["10413","27391431"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10413","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,6]]}}}